EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Recurrent Barrett’s esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up

Thomas Enke, Sridevi K Pokala, Colin Hensen, Case Brennan, Jazmyne Gallegos, Camille J Hochheimer iD, V Raman Muthusamy, Adarsh M Thaker, Vladimir Kushnir, Dayna Early, Amit Rastogi, Hazem Hammad und 3 weitere

Diseases of the Esophagus · 2026

DOI: 10.1093/dote/doag018 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, 2026. Verfasst von Thomas Enke und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Barrett Esophagus, Esophageal Neoplasms, Esophagoscopy. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

US-based data describing long-term outcomes following successful endoscopic eradication therapy (EET) for Barrett’s esophagus (BE) is limited. We assessed the incidence of recurrent BE and BE-related neoplasia and factors associated with recurrent BE in a prospective cohort with long-term follow-up. Patients who underwent EET at four tertiary-care centers from 2013 to 2019 and achieved complete eradication of intestinal metaplasia (CEIM) with ≥5 years of follow-up after CEIM were included. Time-to-event analyses were performed to determine the incidence rate (IR) of recurrent BE and BE-related neoplasia, and a Cox proportional hazards regression model was used to identify factors associated with recurrent BE. Change-point analysis estimated the time at which the rate of recurrent BE changes. A total of 152 patients with a median follow-up of 81.0 months (range 60–155 months) after CEIM were included. Recurrent BE occurred in 57 patients, including 43 (28.3%) with recurrent IM and 14 (9.2%) with BE-related neoplasia. The IR of recurrent BE and recurrent BE-related neoplasia were 6.8 (95% confidence interval [CI] 5.1, 8.8) and 1.3 (95% CI 0.7, 2.2) per 100 person-years, respectively. Baseline histology of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) was the strongest predictor of recurrent BE (hazard ratio 4.4, 95% CI 2.1, 9.0). Recurrent BE peaked at 14 months after CEIM and remained stable thereafter. The IR of recurrent BE-related neoplasia after CEIM is low. The rate of recurrent BE decreases at 14 months and remains stable thereafter and baseline histology of HGD/EAC is the strongest predictor of recurrent BE. These results have implications for guiding endoscopic surveillance. ClinicalTrials.gov ID: NCT02634645.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsEsophagoscopyNeoplasm Recurrence, LocalAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesIncidenceProportional Hazards ModelsProspective StudiesRecurrenceTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Barrett’s esophagusesophageal adenocarcinomaneoplasiarecurrencesurveillance intervals

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Vatche and Tamar Maoukian Division of Digestive Diseases, University of California Los Angeles, Los Angeles, CA, USA.
  • Division of Gastroenterology and Hepatology, Washington University School of Medicine, St Louis, MO, USA.
  • Division of Gastroenterology and Hepatology, University of Kansas School of Medicine, Kansas City, KS, USA.
  • Section of Gastroenterology, King Hussein Cancer Center, Amman, Jordan.

ORCID-Profile: Camille J Hochheimer

Zitieren

APA

Enke, T., Pokala, S. K., Hensen, C., Brennan, C., Gallegos, J., Hochheimer, C. J., Muthusamy, V. R., Thaker, A. M., Kushnir, V., Early, D., Rastogi, A., Hammad, H., Edmundowicz, S. A., Komanduri, S., & Wani, S. (2026). Recurrent Barrett’s esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up. Diseases of the Esophagus. https://doi.org/10.1093/dote/doag018

Vancouver

Enke T, Pokala SK, Hensen C, Brennan C, Gallegos J, Hochheimer CJ, et al. Recurrent Barrett’s esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up. Diseases of the Esophagus. 2026. doi:10.1093/dote/doag018

BibTeX
@article{Enke2026,
  author = {Enke, Thomas and Pokala, Sridevi K and Hensen, Colin and Brennan, Case and Gallegos, Jazmyne and Hochheimer, Camille J and Muthusamy, V Raman and Thaker, Adarsh M and Kushnir, Vladimir and Early, Dayna and Rastogi, Amit and Hammad, Hazem and Edmundowicz, Steven A and Komanduri, Srinadh and Wani, Sachin},
  title = {Recurrent Barrett’s esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up},
  journal = {Diseases of the Esophagus},
  year = {2026},
  doi = {10.1093/dote/doag018}
}
Kostenlos starten →